Sara M Mangsbo
Overview
Explore the profile of Sara M Mangsbo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kerzeli I, Lord M, Doroszko M, Elgendy R, Chourlia A, Stepanek I, et al.
PLoS One
. 2024 May;
19(5):e0304890.
PMID: 38820327
[This corrects the article DOI: 10.1371/journal.pone.0253178.].
2.
Kerzeli I, Nasi A, Fletcher E, Chourlia A, Kallin A, Finnberg N, et al.
Cell Immunol
. 2024 Feb;
397-398:104814.
PMID: 38422979
The aim of this study was to assess the potential use of a selective small molecule MALT1 inhibitor in solid tumor treatment as an immunotherapy targeting regulatory T-cells (Tregs). In...
3.
Ibrahim E, Ellingsen E, Mangsbo S, Friberg L
Int Immunopharmacol
. 2023 Nov;
126:111225.
PMID: 37988911
Therapeutic cancer vaccines are novel immuno-therapeutics, aiming to improve clinical outcomes with other immunotherapies. However, obstacles to their successful clinical development remain, which model-informed drug development approaches may address. UV1...
4.
Kerzeli I, Kostakis A, Turker P, Malmstrom P, Hemdan T, Mezheyeuski A, et al.
BMC Cancer
. 2023 Jun;
23(1):605.
PMID: 37391708
Background: Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). However, recurrences and interventions for intermediate and high-risk NMIBC patients impact the quality of life. Biomarkers for...
5.
Eriksson C, Gunasekera S, Muhammad T, Zhang M, Lauren I, Mangsbo S, et al.
Chembiochem
. 2023 Apr;
24(15):e202300103.
PMID: 37021633
The SARS-CoV-2 virus that causes COVID-19 is a global health issue. The spread of the virus has resulted in seven million deaths to date. The emergence of new viral strains...
6.
7.
Ellingsen E, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, et al.
J Transl Med
. 2022 Sep;
20(1):419.
PMID: 36089578
Background: This clinical trial evaluated a novel telomerase-targeting therapeutic cancer vaccine, UV1, in combination with ipilimumab, in patients with metastatic melanoma. Translational research was conducted on patient-derived blood and tissue...
8.
Ellingsen E, Aamdal E, Guren T, Lilleby W, Brunsvig P, Mangsbo S, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35613827
Background: Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is a second generation telomerase-targeting therapeutic cancer vaccine being investigated across multiple indications....
9.
Mangsbo S, Havervall S, Lauren I, Lindsay R, Falk A, Marking U, et al.
PLoS One
. 2021 Sep;
16(9):e0258041.
PMID: 34591918
Numerous assays evaluating serological and cellular responses have been developed to characterize immune responses against SARS-CoV-2. Serological assays are both cost- and time-effective compared to cellular assays, but cellular immune...
10.
Ellingsen E, Mangsbo S, Hovig E, Gaudernack G
Front Immunol
. 2021 Jul;
12:682492.
PMID: 34290704
Telomerase-based therapeutic cancer vaccines (TCVs) have been under clinical investigation for the past two decades. Despite past failures, TCVs have gained renewed enthusiasm for their potential to improve the efficacy...